Abstract
The current lack of curative options for essential thrombocythaemia (ET) leads to the goal of reducing the risk of potentially life-threatening thrombohaemorrhagic complications with long-term treatment. The setting of relevant treatment targets is an important consideration in this process, allowing the monitoring of disease control. Recent revisions to the World Health Organization (WHO) diagnostic criteria for the chronic MPDs 1 have implications not only for the diagnosis of patients, but also for the management of their disease and the continuing assessment of their progress. The purpose of this article is to discuss recent revisions to the WHO guidelines, and their influence on the setting of treatment targets in patients with ET.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.